Aurora kinases are essential for many aspects of cell division and essential for the normal transition into the G2 checkpoint.82,83 Ilorasertib is an inhibitor of aurora kinases (alongside VEGFRs and PDGFRs) and has been used in clinical trials for tumours with are CDKN2A deficient, the results of which are awaited.84,85. This evidence concerns the gene CDKN2A and neoplasm.